NMTC News and Press, NeuroOne Medical Technologies Corporation From 03/04/22

NeuroOne Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire EDEN PRAIRIE, Minn. , March 4, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focus...

NeuroOne to Present its Game-Changing Neuroscientific Technology at the Oppenheimer 32nd Annual Healthcare Conference and 34th Annual ROTH Conference PR Newswire EDEN PRAIRIE, Minn. , March 3, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ...

NeuroOne® Releases Successful Completion of Long-Term Stimulation Tests for its Novel Thin Film Platform Electrode Technology Successful completion of 5-year stimulation test data presents potential opportunity for long-term applications for Parkinson's disease, epilepsy, s...

NeuroOne Medical Technologies Corporation (NMTC) Q1 2022 Results Conference Call February 14, 2022 4:30 PM ET Company Participants Dave Rosa - Chief Executive Officer Ron Mcclurg - Chief Financial Officer Conference Call Participants Alex Knopick - Craig-Hallum Capital Ben Haynor - Alliance G...

NeuroOne Medical Technologies press release (NASDAQ:NMTC): FQ1 Net loss of $2.8M. Revenue of $0.04M (-55.6% Y/Y). For further details see: NeuroOne Medical Technologies net loss of $2.8M, revenue of $0.04M

NeuroOne Reports First Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update PR Newswire EDEN PRAIRIE, Minn. , Feb. 14, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical techn...

NeuroOne Medical Technologies (NMTC +11.4%) is trading higher after announcing that the company successfully concluded initial pre-clinical testing designed to assess the long-term recording capabilities of its platform thin film electrode technology. NeuroOne (NASDAQ:NMTC) is advancing the m...

NeuroOne® Medical Technologies Corporation Releases Successful Long-Term Recording Test Data for its Novel Thin Film Platform Electrode Technology Successful results of 5-year test data opens potential opportunity for long-term recording applications for Parkinson's disease...

Today there is a massive $13.6 billion neurostimulation devices market developing for the ongoing study of the vast arrays of the brain’s neural connections. (1) The diagnostic electrode technology currently used to detect neurological disorders is the same that was developed way back ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...